CDK4 and breast cancer: Over the past decades, with a better understanding of HR + BC biology, novel biological agents have been investigated such as inhibitors of the cyclin-dependent kinase 4/6 (CDK4/6i), namely palbociclib, ribociclib and abemaciclib.